Abstract
We appreciate the letter regarding our recently published CuVIC trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting).1 As pointed, our notion that the improvement of coronary endothelial function in the ezetimibe plus statin treatment arm compared with statin alone arm might owe to the reductions in oxysterols was based on a post hoc analysis. In the analysis, we generated subgroups (n=62 each) by matching on-treatment low-density lipoprotein cholesterol (LDL-C) levels from the 2 treatment arms; therefore, it was important to assess baseline characteristics of the subgroups. Between the 2 on-treatment LDL-C–matched subgroups, there were no significant differences at the baseline, in background characteristics (sex, age, systolic blood pressure, and ejection fraction) and coronary risk factors (hypertension, diabetes mellitus, dyslipidemia, family …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
